Trials / Conditions / High Risk Smoldering Multiple Myeloma
High Risk Smoldering Multiple Myeloma
7 registered clinical trials studyying High Risk Smoldering Multiple Myeloma — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma NCT06745687 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma NCT06574126 | PETHEMA Foundation | Phase 2 |
| Recruiting | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) NCT05469893 | Irene Ghobrial, MD | Phase 2 |
| Active Not Recruiting | DARA RVD For High Risk SMM NCT04775550 | Omar Nadeem, MD | Phase 2 |
| Terminated | Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients NCT02943473 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Completed | Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilo NCT02697383 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma NCT01484275 | Janssen Research & Development, LLC | Phase 2 |